Skip to main content
SclerodermaLungs and breathingDrugPhase 2

What this study is

This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.

What's being tested

  • Sildenafil

    Intervention · DRUG

    Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.

  • Placebo

    Intervention · OTHER

    Oral pill placebo.

Study details

Sponsor
Johns Hopkins University
Conditions
Scleroderma · Mildly Elevated Pulmonary Pressures
Enrolling
30 people
Starts
2021-09-20
Est. completion
2026-11-01
Design
Quadruple-blind, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗